ovarian%20mass
OVARIAN MASS
Ovarian cysts are typically noted after clinical screening, or as a result of exam for a suspected pelvic mass, or an incidental finding in investigations done for other reasons.
Most ovarian masses manifest with few or mild nonspecific symptoms.
Ovarian masses in women of reproductive age are mostly benign but the risk of malignancy increases with age.
Ovarian cysts in the prepubertal patients especially after the first week of life are abnormal and likely to be neoplastic. In adolescent patients, majority of ovarian masses are functional cysts.

Monitoring

Postmenopausal Woman 

  • Small (<5 cm), simple, unilocular, unilateral ovarian cysts in asymptomatic patients can be followed conservatively
  • Repeat transvaginal ultrasound and serum CA-125 should be performed at 3- to 4-month intervals x 1 year to check for any change in size or development of suspicious features
    • 50% of asymptomatic cysts resolve within 2 months
  • Consider surgical management for women with moderate- to high-risk Risk of Malignancy Index (RMI) or for those who do not qualify for conservative management

Conservative Management

  • Asymptomatic, simple, unilateral, unilocular ovarian cysts <3-5 cm in diameter have a low risk of malignancy and if CA-125 is normal, the woman may be managed conservatively

Expectant Management in Premenopausal Patient

  • Conservative observation can be adopted for complex or solid ovarian cysts of benign character (<8 cm in diameter, unilateral, unilocular, cystic, mobile, smooth, solid component is <7 mm, positive acoustic shadowing, absent blood flow) with ultrasound surveillance every 2-3 months
  • Follow-up is not required for simple ovarian cysts <5 cm as it usually spontaneously resolves, follow-up with ultrasound every 3-4 months for 5- to 7-cm cysts, and consider further imaging or surgical referral for larger simple cysts
    • Laparoscopic cystectomy may be done if surgery is required
  •  70% of benign ovarian masses will resolve spontaneously by either reabsorption of the cyst fluid or silent rupture within 4-8 weeks of initial diagnosis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
17 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.